GENERIC NAME OF THE MEDICINAL PRODUCT:

A. Lopinavir and Ritonavir Tablets USP (200mg+50mg)
B. Lopinavir and Ritonavir Tablets USP (100mg+25mg)

QUALITATIVE AND QUANTITATIVE COMPOSITION:

A. Lopinavir and Ritonavir Tablets USP (200mg+50mg)
Composition:
Each film-coated tablet contains:
Lopinavir USP…………………….….200mg
Ritonavir USP……………………50mg
Excipients…………………………. q.s.
Colours: Titanium Dioxide USP


B. Lopinavir and Ritonavir Tablets USP (100mg+25mg)
Composition:
Each film-coated tablet contains:
Lopinavir USP…………………….….100mg
Ritonavir USP……………………25mg
Excipients…………………………. q.s.
Colours: Iron Oxide Red

THERAPEUTIC INDICATIONS:

Lopinavir and ritonavir tablets are indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients (6 months and older weighing at least 15 kg).
Direct acting antivirals.
Nucleoside and Nucleotide reverse transcriptase inhibitors.

CAUTION & WARNING:

CAUTION: Do not throw away consumer package insert.
Swallow whole do not chew or crush.
WARNING: Do not skip/discontinue the dose for effective treatment.
Do not stop taking your medicine or change your dosage without consulting your doctor.
***Suitable for Vegetarians & Vegans.
Keep out of the reach and sight of children.

STORAGE & DOSAGE:

Storage: Store protected from moisture at a temperature not exceeding 25°C.
Dosage: As directed by the Physician.

Lopinavir and Ritonavir Tablets USP (200mg+50mg) Technical Specification:

Product Name:Lopinavir and Ritonavir Tablets USP (200mg+50mg)
Brand Name:Generics
Strength:(200mg+50mg), (100mg+25mg)
Dosage Form:Film-coated tablets
Packing:120 Tab Bottle
Route of Administration:For Oral Use Only
Pack Insert/Leaflet:PIL (Patient Information Leaflet), SmPC (Summary Product Characteristics)
Regulatory Documents:COA, MOA, COPP, FSC, Stability Studies, GMP, CTD Dossier
Therapeutic use:Antivirals
Indication: Lopinavir and ritonavir tablets are indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients (6 months and older weighing at least 15 kg).
Storage:Store protected from moisture at a temperature not exceeding 25°C.

GENERIC NAME OF THE MEDICINAL PRODUCT:

  • Lopinavir and Ritonavir Tablets USP (200mg+50mg)

QUALITATIVE AND QUANTITATIVE COMPOSITION:

  • Lopinavir and Ritonavir Tablets USP (200mg+50mg)
    Composition:
    Each film-coated tablet contains:
    Lopinavir USP…………………….….200mg
    Ritonavir USP……………………50mg
    Excipients…………………………. q.s.
    Colours: Titanium Dioxide USP

THERAPEUTIC INDICATIONS:

Lopinavir and ritonavir tablets are indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients (6 months and older weighing at least 15 kg).

Direct acting antivirals.

Nucleoside and Nucleotide reverse transcriptase inhibitors.

CAUTION & WARNING:

CAUTION: Do not throw away consumer package insert.

Swallow whole do not chew or crush.

WARNING: Do not skip/discontinue the dose for effective treatment.

Do not stop taking your medicine or change your dosage without consulting your doctor.

 ***Suitable for Vegetarians & Vegans.

Keep out of the reach and sight of children.

STORAGE & DOSAGE:

Storage:  Store protected from moisture at a temperature not exceeding 25°C.

Dosage: As directed by the Physician.